MAMTA KALIDAS

Concepts (106)

Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.


Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Breast Neoplasms
9
2010
2479
0.410
Why?
Raloxifene Hydrochloride
1
2004
16
0.240
Why?
Estrogen Receptor Modulators
1
2004
38
0.240
Why?
Aromatase Inhibitors
1
2005
75
0.240
Why?
Selective Estrogen Receptor Modulators
1
2004
60
0.230
Why?
Antineoplastic Agents, Hormonal
1
2004
254
0.210
Why?
Self Concept
3
2010
157
0.200
Why?
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
2001
98
0.180
Why?
Guilt
3
2010
15
0.170
Why?
Spirituality
3
2010
48
0.160
Why?
Adaptation, Psychological
4
2010
461
0.140
Why?
Taxoids
2
2005
65
0.110
Why?
Motivation
2
2006
314
0.110
Why?
Quality of Life
4
2010
1924
0.090
Why?
Randomized Controlled Trials as Topic
2
2005
1074
0.090
Why?
Sick Role
2
2006
31
0.080
Why?
Survivors
1
2010
345
0.070
Why?
Chemotherapy, Adjuvant
2
2005
353
0.070
Why?
Public Sector
1
2006
13
0.070
Why?
Attitude
1
2007
118
0.070
Why?
Breast Diseases
1
2006
34
0.070
Why?
Social Adjustment
1
2006
85
0.060
Why?
Mastectomy, Segmental
1
2005
27
0.060
Why?
Nitriles
1
2005
145
0.060
Why?
Antineoplastic Agents, Phytogenic
1
2005
101
0.060
Why?
Triazoles
1
2005
138
0.060
Why?
Neoplasm Staging
2
2005
1213
0.060
Why?
Social Support
1
2006
345
0.060
Why?
Multicenter Studies as Topic
1
2004
261
0.060
Why?
Depression
2
2010
1227
0.060
Why?
Drug Administration Schedule
1
2005
720
0.050
Why?
Antineoplastic Agents
2
2003
1660
0.050
Why?
Tamoxifen
1
2005
363
0.050
Why?
Personality Inventory
3
2010
166
0.050
Why?
Patient Acceptance of Health Care
1
2006
419
0.050
Why?
Genes, abl
1
2001
7
0.050
Why?
Genes, cdc
1
2001
25
0.050
Why?
Imatinib Mesylate
1
2001
44
0.050
Why?
Dose-Response Relationship, Drug
1
2005
1681
0.050
Why?
Benzamides
1
2001
106
0.050
Why?
Research Design
1
2004
676
0.040
Why?
Drug Resistance, Neoplasm
1
2005
714
0.040
Why?
Clinical Trials as Topic
1
2004
1081
0.040
Why?
Survival Rate
1
2005
2000
0.040
Why?
Interferon-alpha
1
2001
221
0.040
Why?
Piperazines
1
2001
230
0.040
Why?
Risk Assessment
2
2006
3327
0.040
Why?
Iron
1
2001
262
0.040
Why?
Pyrimidines
1
2001
375
0.040
Why?
Female
9
2010
65562
0.040
Why?
Gene Expression Profiling
1
2005
1679
0.040
Why?
Middle Aged
6
2010
26015
0.040
Why?
Antibodies, Monoclonal
1
2003
1009
0.040
Why?
Hematopoietic Stem Cells
1
2001
533
0.040
Why?
Incidence
1
2004
3045
0.030
Why?
Macrophages, Peritoneal
1
1997
38
0.030
Why?
Macrophage Activation
1
1997
62
0.030
Why?
Amphotericin B
1
1997
90
0.030
Why?
Candida albicans
1
1997
76
0.030
Why?
Hospitals, Public
2
2006
38
0.030
Why?
Humans
11
2010
123180
0.030
Why?
Follow-Up Studies
1
2005
5040
0.030
Why?
Adult
5
2007
29032
0.030
Why?
Apoptosis
1
2001
1782
0.030
Why?
Antifungal Agents
1
1997
286
0.030
Why?
Surveys and Questionnaires
3
2010
3670
0.030
Why?
Aged
3
2006
19108
0.030
Why?
Hematopoietic Stem Cell Transplantation
1
2001
1199
0.030
Why?
Socioeconomic Factors
2
2006
864
0.030
Why?
Neoadjuvant Therapy
2
2005
321
0.030
Why?
Treatment Outcome
2
2005
12142
0.020
Why?
Oligonucleotide Array Sequence Analysis
2
2005
1012
0.020
Why?
United States
1
2004
10660
0.020
Why?
Texas
2
2006
3565
0.020
Why?
Uncompensated Care
1
2006
10
0.020
Why?
Hospitals, General
1
2006
24
0.020
Why?
Health Surveys
1
2006
242
0.020
Why?
Attitude to Health
1
2006
260
0.010
Why?
Ambulatory Care Facilities
1
2006
229
0.010
Why?
Genes, erbB-2
1
2003
37
0.010
Why?
Mastectomy
1
2003
64
0.010
Why?
Trastuzumab
1
2003
131
0.010
Why?
Poverty
1
2006
418
0.010
Why?
Referral and Consultation
1
2006
529
0.010
Why?
Multivariate Analysis
1
2005
1415
0.010
Why?
Psychometrics
1
2005
665
0.010
Why?
HL-60 Cells
1
2001
31
0.010
Why?
Tetradecanoylphorbol Acetate
1
2001
68
0.010
Why?
Neoplasm Metastasis
1
2003
654
0.010
Why?
Health Knowledge, Attitudes, Practice
1
2006
828
0.010
Why?
Antibodies, Monoclonal, Humanized
1
2003
489
0.010
Why?
Anxiety
1
2006
961
0.010
Why?
Kinetics
1
2001
1312
0.010
Why?
Reproducibility of Results
1
2005
2840
0.010
Why?
Cross-Sectional Studies
1
2006
3375
0.010
Why?
Microscopy, Electron, Scanning
1
1997
153
0.010
Why?
Drug Carriers
1
1997
100
0.010
Why?
Liposomes
1
1997
169
0.010
Why?
Aged, 80 and over
1
2006
6375
0.010
Why?
Cell Differentiation
1
2001
1909
0.010
Why?
Gene Expression Regulation
1
2001
2524
0.010
Why?
Cells, Cultured
1
1997
3040
0.010
Why?
Adolescent
1
2006
19111
0.000
Why?
Male
1
2006
60173
0.000
Why?
Mice
1
1997
17542
0.000
Why?
Animals
1
1997
33798
0.000
Why?
KALIDAS's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (106)
Explore
_
Co-Authors (5)
Explore
_
Similar People (60)
Explore
_
Same Department Expand Description
Explore
_